The effects of Apigenin on EMT were evaluated in vitro and in vivo using highly metastatic breast cancer cells (MDA-MB-231 cell line) that endogenously expressed the pro-EMT, interleukin-6 (IL-6) [44]. The gene discussed is IL6; the disease is breast carcinoma.